Surufatinib

Neuroendocrine Tumors

Shanghai Changzheng HospitalSmall moleculePhase 3Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 59/ 100
Competitive Position: 73/ 100

Competitive context

61 Active assets in the Neuroendocrine Tumors cohort.

Asset / Sponsor	Phase	Rating
FLUOROURACILUM ITM Solucin GmbH	Phase 3	BB
Irinotecan First Affiliated Hospital Xi'an Jiaotong University	Phase 4	BB
Bms-907351 Fox Chase Cancer Center	Phase 3	BB
Eloxatin ITM Solucin GmbH	Phase 3	BB
Pasireotide RECORDATI GROUP	Phase 4	BB

View all 50 →

Same molecule, other indications

Surufatinib is also rated in:

malignant pancreatic neoplasmDormant

BB

Indicative ·

65 / 100

colorectal cancerDormant

B

Indicative ·

58 / 100

pancreatic ductal adenocarcinomaDormant

B

Indicative ·

58 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.